318 related articles for article (PubMed ID: 37966552)
1. EMT-induced immune evasion: connecting the dots from mechanisms to therapy.
Imodoye SO; Adedokun KA
Clin Exp Med; 2023 Dec; 23(8):4265-4287. PubMed ID: 37966552
[TBL] [Abstract][Full Text] [Related]
2. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1.
Hu B; Tian X; Li Y; Liu Y; Yang T; Han Z; An J; Kong L; Li Y
Cancer Med; 2020 Apr; 9(8):2686-2697. PubMed ID: 32077634
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance.
Singh D; Siddique HR
Cancer Metastasis Rev; 2024 Mar; 43(1):155-173. PubMed ID: 37775641
[TBL] [Abstract][Full Text] [Related]
5. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
Datar I; Schalper KA
Clin Cancer Res; 2016 Jul; 22(14):3422-4. PubMed ID: 27076625
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.
Mullins RDZ; Pal A; Barrett TF; Heft Neal ME; Puram SV
Cancer Res; 2022 Jul; 82(13):2329-2343. PubMed ID: 35363853
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
9. SPOCK1, as a potential prognostic and therapeutic biomarker for lung adenocarcinoma, is associated with epithelial-mesenchymal transition and immune evasion.
Liu Y; Han T; Wu J; Zhou J; Guo J; Miao R; Xu Z; Xing Y; Bai Y; Hu D
J Transl Med; 2023 Dec; 21(1):909. PubMed ID: 38087364
[TBL] [Abstract][Full Text] [Related]
10. Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells.
Singh S; Chakrabarti R
J Clin Med; 2019 May; 8(5):. PubMed ID: 31075939
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
12. New insights into the role of EMT in tumor immune escape.
Terry S; Savagner P; Ortiz-Cuaran S; Mahjoubi L; Saintigny P; Thiery JP; Chouaib S
Mol Oncol; 2017 Jul; 11(7):824-846. PubMed ID: 28614624
[TBL] [Abstract][Full Text] [Related]
13. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
Liao TT; Yang MH
Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
[TBL] [Abstract][Full Text] [Related]
14. Do Tumor Mechanical Stresses Promote Cancer Immune Escape?
Onwudiwe K; Najera J; Siri S; Datta M
Cells; 2022 Nov; 11(23):. PubMed ID: 36497097
[TBL] [Abstract][Full Text] [Related]
15. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.
Wang G; Xu D; Zhang Z; Li X; Shi J; Sun J; Liu HZ; Li X; Zhou M; Zheng T
NPJ Precis Oncol; 2021 Jun; 5(1):56. PubMed ID: 34158591
[TBL] [Abstract][Full Text] [Related]
16. The Role of Tumor Epithelial-Mesenchymal Transition and Macrophage Crosstalk in Cancer Progression.
May AM; Batoon L; McCauley LK; Keller ET
Curr Osteoporos Rep; 2023 Apr; 21(2):117-127. PubMed ID: 36848026
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion.
Shao X; Hua S; Feng T; Ocansey DKW; Yin L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233088
[TBL] [Abstract][Full Text] [Related]
18. TGF-β, EMT, and resistance to anti-cancer treatment.
Wang X; Eichhorn PJA; Thiery JP
Semin Cancer Biol; 2023 Dec; 97():1-11. PubMed ID: 37944215
[TBL] [Abstract][Full Text] [Related]
19. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.
Rajabi H; Kufe D
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):117-122. PubMed ID: 28302417
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
